21st.BIO

This Wednesday, our co-founder and CSO Per Falholt and our colleague Barbara Taudorf Andersen joined key players of the Danish and European biosolutions scene for the second Biosolutions summit.   This event was a manifestation of the potential of biosolutions, and of the companies redefining the biotech industry in Denmark.   Mads Krogsgaard Thomsen, CEO at the Novo Nordisk Foundation, and Ester Baiget, CEO at Novonesis, lead the way stating that:   💶 It is time to subsidize the future – instead of subsidizing the past. We have the experience: to get new solutions to market, they need support. Especially when the competing solutions are subsidized.   🍀 Sustainable solutions (i.e products produced with biology) are competitive – when the hidden cost of traditional animal-based products is taken into account.   It was great to hear Arla Foods state that the future can't be animal production vs. alternative sources. To feed the growing population, we need both.   Danish Minister for Industry, Business, and Financial Affairs, Morten Bødskov, clearly stated that structural changes are needed to create a European home market.   Our co-founder and CSO Per Falholt presented 21st.BIO's work and shared important takeaways: ▶ There is a black swan coming towards our global food systems. The growing and ageing population needs more nutritious food, and current production is capped. ▶ Biosolutions are being scaled already and can redefine the capabilities of all regions to reach self-sufficiency. ▶ Europe owns the leading technology – but we will fall behind if we do not establish large scale manufacturing of protein in Denmark and other EU countries, as well as fast-track 3-5 proteins to get these products to market in Europe.   Many thanks to the European Biosolutions Coalition, DI Bio, the Alliance for Biosolutions, and Sofie Carsten Nielsen for the organization and support. Thank you all for the inspiring discussions and presentations. 

Meet our co-founder and CEO Thomas G. Schmidt and our colleague Barbara Taudorf Andersen, Director Commercial Development and Strategic Partnerships, at the upcoming Gulfood Manufacturing FoodTech Summit next week in Dubai.   🗓 Mark your calendars: on Wednesday 6th November, at 14:50, Thomas will be part of the panel discussion "Exploring innovations and investments in alternative proteins".   With over 2,500 exhibitors from 72 countries, Gulfood Manufacturing is a reference for food and beverages manufacturers globally. As the food industry is facing unprecedented challenges — climate change impact on yields, soaring raw materials costs, supply chain disruptions, unrelenting sustainability demands — new technologies are needed for a more secure, resilient, and nutritious food supply.   We at 21st.BIO are building the first concrete platform for sustainable food production at scale, powered by precision fermentation.   The panel discussion is an opportunity to hear Thomas G. Schmidt sharing knowledge and advice on: ➡ How we can use precision fermentation to close the protein gap. ➡ His perspective on the future of precision fermentation in production of high-quality nutrition. ➡ Production upscaling strategies to reach industrial production of proteins. Planning to attend? Reach out already and book a meeting with Barbara Taudorf Andersen and Thomas G. Schmidt. 

We're very proud to make the cover of Berlingske Business, sharing that precision fermentation can be the key to secure food and climate resilience 📰   In the article, our CEO Thomas G. Schmidt explains that it is time to add another production technology to produce foods and materials for the world. A clean, green, resilient, efficient, consistent, and fast-paced solution is ready to take over: precision fermentation.   Denmark and Europe should leverage their world-leading position in precision fermentation and establish large scale manufacturing capacity in Denmark to produce nutritious proteins. Cow's milk proteins provide an unmatched balance of complete nutrition, functional benefits, and versatility. With 21st.BIO's production technology food manufacturers across the globe, are now able to produce these proteins – using precision fermentation technology instead of cows.   Precision fermentation technology is a Danish pride, fueling the global successes of Novo Nordisk and Novonesis. Building on this legacy, 21st.BIO is now developing the technology for new areas of application: nutritious foods, agriculture, biomaterials, and even biomining.   For this, huge production volumes are required. That's why we need mega production facilities to be built – ideally, in Europe, where we have the leading technology.   "Denmark has a unique ecosystem for large-scale biomanufacturing. We have the technology, the knowledge, and the skilled people who know how to put it together. Protein manufacturing could easily be our next wind turbine adventure. But there are plenty of headwinds in Denmark, and that's unfortunate," Thomas told Berlingske.   Our customers are already upscaling their production of the amazing whey protein, beta-lactoglobulin (BLG). Our production technology, BLG Essential+™, has already been approved in the USA. But it will take many years until you can find it in European products... While many biosolutions leaders are based in Europe, the EU legislators are too slow to adapt.   The EU and Denmark may be missing an opportunity as other countries ramp up their investments. It's not too late to take a U-turn and change the game to secure that Europe can leverage financially on this technology advancement.   "But if it's going to happen, we have to decide on it. A full-scale protein factory in Denmark will probably be a bit more expensive than if we built it in other countries and will require some government support. But if we build the first few, then they can be copied, and we will be able to sell hundreds around the world." Many thanks to Vibeke Lyngklip Svansø for this great piece.   Read the full article here: https://lnkd.in/d3XZUfSp   #EU #Food #Biotech

We're in the news again 📰 Our CEO Thomas G. Schmidt talked about the role of precision fermentation in the future of food, and how Denmark as a country may miss an opportunity in the field as other countries ramp up their investments.   Precision fermentation is a powerful technology with gigantic potential. While many precision fermentation companies emerge and develop in Europe, their success stories often mean a relocation across the Atlantic to the USA.   The USA, among other countries, invest heavily in precision fermentation as part of their security and self-sufficiency policies. They recognize the strategic importance of precision fermentation technology to secure future supply in nutritious food, materials, and agriculture.   The European Union and Denmark must work harder to stay competitive in a changing environment.   There's lots of work to be done to get there, and we're not shying away from it. At 21st.BIO, we're taking our part, developing the most advanced precision fermentation technology and making it accessible and affordable for all industry players. With our pilot plant fully operational, we help our customers upscale their production towards commercially-relevant levels.   But that won't be enough to feed the world. We will need many industrial-scale production facilities. And for this, we need the EU and Danish governments to: ➡ Change agricultural subsidies to favor new production technologies. ➡ Collaborate with the farmers organizations to ensure a transition towards a new production model ➡ Speed up regulatory approval to allow Europeans access to high quality nutrition and ensure self-sufficient supply in EU ➡ Establish a first mega protein factory in Denmark, securing strategic food supply and job opportunities.   Thank you to Sjællandske Medier and Anders Rostgaard Birkmann for visiting us and showcasing our story. #Biotech #Biomanufacturing #Sustainability

Meet us at CPHI! Our colleague Rasmus Rune Hansen, Director of Client Development and Project Management, is on the ground in Milan, eager to connect with industry innovators interested in precision fermentation.   At 21st.BIO, we empower our customers with the world-leading precision fermentation tech, know-how, and expertise needed to produce top-quality nutraceuticals and compounds for pharmaceutical applications, at an industrial scale for competitive pricing.   Precision fermentation is gaining attention for its sustainability, supply chain security, enhanced product consistency, animal-free production, customizability, reduced resource use, and innovative ingredient development. Imagine leveraging our strains and technology to produce...  ☑ A truly vegan collagen with the same structure and benefits as animal-sourced molecules ☑ The dairy proteins beta-lactoglobulin (the main whey protein) and caseins, offering versatile applications thanks to their both nutritious and functional properties ☑ Growth factors tailored for pharma applications ☑ ... or any protein of interest to you.   Whether you're interested in nutraceuticals or pharma compounds, connect with Rasmus to explore how we can help turn your ingredient vision into reality.   #PrecisionFermentation #Nutraceuticals #Pharma

Last week, our brilliant science team met for the annual #TechWeek to accelerate our journey in precision fermentation and the potential to change the food, materials and agricultural industry.   A week of collaboration and creativity, our #TechWeek is a time dedicated to sharing the latest breakthroughs, future technology roadmaps, and ideas for how we continue to shoot for the moon with our cutting edge R&D. And a time to discuss how we continue to translate this work into delivering leading production technology empowering our customers to get to market faster with the most efficient product.   The program is a great mix of internal update presentations and guest lectures. Our talented colleagues across the strain engineering, fermentation, pilot facility, downstream processing, production upscaling, analytics, automation, as well as IP and regulatory affairs are all present and sharing their work.   Taking place at our site in Davis, California, this week is all about pushing the boundaries of what's possible with precision fermentation. At 21st.BIO we help people who change the world.   #PrecisionFermentation #Research #Biotech

It was a pleasure hosting Ester Baiget, President and CEO of Novonesis, and Tue Micheelsen, VP and President of North America, at our 21st.BIO Davis office.     During their visit, we showcased our latest advancements in strain engineering, fermentation, and biomanufacturing.     Our production strains, partly based on technology licensed from Novonesis – a global leader in biosolutions and an investor in 21st.BIO – are a testament to our joint R&D expertise.     The techology base licensed from Novonesis has been developed and optimized for large scale production over decades. Our work, built on this strong foundation, has led to strains and fermentation protocols which are powerful production tools to unlock the potential of protein- and peptide-based innovations.     At 21st.BIO, we grant our customers a high-performance platform with optimized fermentation protocols for multiple expression systems. This provides risk-mitigated, high-performance solutions to large-scale bioproduction across various industries.     We continuously expand our portfolio with more and more proteins and peptides serving the nutrition, food, agriculture, biomaterials, and even biomining industries. We work hard to improve titers and optimize processes, ensuring our customers can stay ahead of the market – long term.     We’re very proud to build on the legacy of the Novo Group and Novonesis in particular. Thank you for your visit, Ester and Tue!

I had the pleasure of speaking with Børsen and journalist Peter B. Rasmussen about the crucial steps needed to maintain Denmark and Europe’s leadership in biotechnology.     As we continue to make groundbreaking strides in biosolutions and fermentation technology, it's clear that the government has a key role in securing our competitive edge.    Denmark has for a long time been a global leader in fermentation processes — powering industries from medicine and enzymes to food production. But as we look to the future, we must ensure that the biotech industry has the support and infrastructure it needs to scale and succeed.    The potential in nutrition and materials is enormous, and with the right backing. Danish biosolutions could be at the center of providing better nutrition and distinctly new materials in an environmentally friendly way.    A significant investment in new fermentation plants across the world is required and will come. Danish Industry has proposed more direct governmental support and investments in EU and Denmark. This could help ensure that innovation is accelerated in Europe.     Read our statement in Børsen today: https://lnkd.in/d84vviBN     

We have massive news: 21st.BIO has obtained self-affirmed GRAS status for our beta-lactoglobulin ingredient, BLG Essential+™. This means our customers can now enter the U.S. market with their own production using our precision fermentation technology.    This breakthrough comes less than two years after we first initiated our development of beta-lactoglobulin. It’s concrete proof of the value and support we offer our customers to bring products to market, at an unprecedented pace.     While it is a major milestone for 21st.BIO, it is also huge news for the entire industry. For the first time, one market approval means multiple market entries for an alternative protein.     The predominant protein in bovine whey, beta-lactoglobulin (BLG) has attracted considerable food-producer interest for its high-quality nutrition and advantageous properties in food product formulation. ✅ Boasting a larger amount of essential and branched-chain amino acids than whey, BLG Essential+™ contains 45% more leucine than commercially available whey protein isolates, which is particularly important for muscle synthesis. ✅ It is tasteless, stable across a wide pH range and can tolerate heat, making it the ideal ingredient for versatile product formulations, from clear protein drinks to alternative dairy products or even baked goods.   Our business model is unique and it allows more players in the market to access our production technology and scale it for their own functionality and purpose.     Massive shout-out to our fantastic team who worked so hard to make it happen. And of course, big congrats to our customers who can now commercialize their production in the U.S. market.    Read our press release: https://lnkd.in/era8fwCq   #Food #Bioproduction #AlternativeProteins

Denmark is world-leader in fermentation with a unique ecosystem for fermentation-based production. Now, it's time for Denmark to take the lead as large scale producer of nutrition and materials with fermentation by building biofactories. 21st.BIO supports Denmark’s largest Industry organisation, Danish Industry, advocating for the Danish government to co-finance the development of biofactories alongside private partners.  Denmark is already a global leader in biosolutions, with cutting-edge companies and strong research environments. This sector has deep roots in Danish history. However, the necessary infrastructure to produce at industrial scale has to be established to leverage the potential. Today, we're on the brink of another significant leap forward. There seems to be a growing consensus that we need large-scale fermentation facilities established in Denmark to propel the next industry driving the production of nutrition and materials with new benefits and a radically improved footprint on our environment and resources. It is not only for the climate. If we do not build a bioproduction footprint, companies may move production abroad, costing Denmark its next big industrial adventure. That's why it is encouraging that an important player like Danish industry is proposing to the Danish government to invest in biofactories.  With government involvement, private investors are likely to follow suit, ensuring Denmark remains at the forefront of the biosolutions industry. #biosolutions #biomanufacturing #biotechnology DI Bio